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Aim: The aim of our open prospective randomized nutritional intervention study was to
evaluate the effect of feeding with a standard infant formula enriched with the speciﬁc
mixture of oligosaccharides on local digestive immunity system and further development
of allergic and infectious diseases in young children. Material and methods: Depending
on the type of feeding the infants were divided into 3 groups (with random allocation to
one of the formula feeding groups): 80 infants who were breastfed, 80 infants consuming
the formula supplemented with oligosaccharides, 80 infants fed with a standard formula.
Results: Breastfed infants had the highest content of Biﬁdobacteria and Lactobacilli in
feces (9.047  1.075 and 7.26  0.65 CFU/g accordingly). In infants fed with formula sup-
plemented with scGOS/lcFOS fecal concentrations of Biﬁdobacteria and Lactobacilli were
similar to those in breastfed infants (8.92  1.011 and 7.22  0.74 CFU/g accordingly). It
was found that infants fed with breast milk and supplemented formula had signiﬁcantly
less allergic reactions to food products compared to the babies from the third group
(3.92% and 4.84% vs. 16.98% accordingly; p < 0,05). Conclusions: The mixture of prebiotic
oligosaccharides (scGOS/lcFOS – 9:1; 8 g/L) has a similar to breast milk positive impact on
the factors of local digestive immunity system in formula-fed infants. This effect may
reduce the risk of allergic and infectious diseases in children aged up to 18 months of
life, compared with babies fed with the standard formula without oligosaccharides.
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rights reserved.
* Corresponding author at: Lviv National Medical University, Department of Pediatrics, Pekarska 69, 79010 Lviv, Ukraine.
Tel.: +38 0677734744.
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/locate/pepoE-mail address: niank@mail.lviv.ua (S.L. Nyankovskyy).
0031-3939/$ – see front matter © 2013 Polish Pediatric Society. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
http://dx.doi.org/10.1016/j.pepo.2013.07.002
p e d i a t r i a p o l s k a 8 8 ( 2 0 1 3 ) 3 9 8 – 4 0 4 399Introduction
The inﬂuence of breast milk on the development of immu-
nity was known many years ago. Human milk oligosaccha-
rides have inﬂuence on the development of immunity and
morbidity in infants. The type of diet is one factor that
determines the composition of the intestinal microﬂora of
breast-fed infants, which differs from the microﬂora of
bottle-fed infants [1, 2]. In breastfed infants, the intestinal
microﬂora is dominated by Biﬁdobacteria and Lactobacilli,
and this microbial pattern produces beneﬁcial effects on
intestinal function and on development of the immune
system [2, 3].
Based on the analysis of human milk oligosaccharides
(HMO), a prebiotic mixture of 90% short chain galactooligo-
saccharides and 10% long chain fructo-oligosaccharides
(scGOS/lcFOS (9:1; 8 g/L)) has been developed [4, 5].
Studies in preterm [6] and term [2, 7–8] infants have
shown that feed supplementation with GOS/FOS produces
an intestinal ﬂora similar to that found in breast fed infants.
Study showed that the use of this prebiotic oligosaccharide
mixture (scGOS/lcFOS) can signiﬁcant reduction of the total
number of infections, respiratory tract infections, fever
episodes, and antibiotic prescriptions during the ﬁrst 2 y of
life. The atopic dermatitis (AD), cumulative incidence of
other allergy-associated symptoms, like recurrent wheezing
and allergic urticaria, was also signiﬁcantly lower in the
sGOS/lcFOS group compared with the placebo group [9].
Our hypothesis was that this mixture of prebiotic oligo-
saccharides could mimic the immune modulatory function
of HMO on local immunity factors, protect mucous membra-
nes of the digestive system, and lead to a reduction in the
incidence of allergic and infectious diseases in formula-fed
infants. To test this hypothesis, we have planned and
conducted an open prospective randomized nutritional
intervention study.
Aim of the study
The aim of our study was to evaluate the effect of feeding
with a standard infant formula enriched with the speciﬁc
mixture of oligosaccharides (scGOS/lcFOS; 9:1; 8 g/L) compa-
red to a formula without oligosaccharides and breastfeeding
during the ﬁrst months of life on digestive system local
immunity and further development of allergic and infec-
tious diseases in young children.
Materials and methods
Two hundred and forty healthy term newborns were invol-
ved into the study on its ﬁrst stage. Depending on the type
of feeding the infants were divided into 3 groups (with
random (sealed envelope randomization) allocation to one
of the formula feeding groups): the group 1 included 80
infants who were breastfed, the group 2 – 80 infants
consuming the formula supplemented with a speciﬁc mix-
ture of oligosaccharides, and the group 3 – 80 infants fedwith a standard formula (Fig. 1). Enrollment into the second
and the third groups took place only if mothers had decided
not to breastfeed. Infants were supposed to be breastfed or
fed with the allocated formula for at least 2 months.
Babies in the groups did not differ by age at the
enrollment, gender, physical and social settings. Participa-
tion in the study was voluntary with signing of informed
consent by parents. This study was approved by a local
Ethics Committee.
Inclusion criteria were:
 Healthy term newborns with birth weight >2500 g appro-
priate for gestational age.
 Apgar scores >7.
 Uncomplicated early course of neonatal period.
 Impossibility of breastfeeding (for infants randomized into
the bottle-feeding groups).
 Informed consent was signed by parents.
Exclusion criteria:
 The minimum possibility of breastfeeding (for infants
randomized into the bottle-feeding groups).
 Administration of probiotics and prebiotics before involve-
ment into the study.
Growth parameters (weight, length, head circumference,
and BMI) were determined at enrollment, in 2 and at 18
months.
Saliva and fecal samples were taken on the day of
inclusion into the study and after 2 months of exclusive
feeding with the selected formula or breast milk. Saliva sIgA
(sIgA ELISA «Khem@-Medica» Ltd), alpha-defensins HNP1-3
(HNP 1-3 ELISA KIT) and fecal lysozyme (Human LL-37 ELISA
TEST KIT) were determined by an ELISA method. Gut
microbiota composition was assessed in 2 months after
beginning of the study using standard bacteriological
methods. Biﬁdobacteria, Lactobacilli and Candida fungi have
been analyzed.
By the end of the second phase of the study, we compared
the cumulative incidences of atopic dermatitis (AD), obstruc-
tive bronchitis, recurrent wheezing, gastrointestinal and
upper respiratory tract infections (URTI) at 18 months depen-
ding on type feeding in the ﬁrst months of life.
AD was diagnosed according to the criteria described by
Harrigan and Rabinowitz [10] and Muraro et al. [11]. The
diagnosis of AD was conﬁrmed if the following features
were detected: pruritus, involvement of the face, skull facial,
and/or extensor part of the extremities, and a minimal
duration of the symptoms of 4 weeks. Recurrent wheezing
was deﬁned as 3 or more physician-diagnosed wheezing
episodes [13]. Ofﬁcial medical documents and reports were
used.
By the end of the study, the number of children in
groups decreased (Fig. 1). The main reasons for dropping out
were failure to follow up, poor compliance, change of
feeding type, for example, lack of breast milk or replace-
ment of the preselected formula in the bottle-fed groups.
Statistical analysis
Standard methods of descriptive, comparative and categori-
cal analyses were used. If normally distributed continuous
Enrollment (n  = 24 0) 
Group 1 
(n = 80 ) babies on 
breast-feeding 
Group 2 
(n = 80 ) babies on formula 
fee ding wit h scGOS /lc FOS 
Group 3 
(n = 80 ) babies on formula 
fee ding wit hout oli gosaccharides  
Randomiz aon 
Results aer 2 months 
Group 1 
(n = 66) babies on 
breast-feeding 
Group 2 
(n = 65) babies on formula 
fee ding wit h scGOS /lc FOS 
Group 3 
(n = 64) babies on formula 
fee ding wit hout 
oli gosaccharides 
Followed up to 18 mo nths  
Group 2 
(n = 62) babies 
completed the study  
Group 3 
(n = 53) babies 
completed the study  
Group 1 
 (n = 51) babies 
completed the study 
Assess ed for eli gibil ity 
(n = 287) 
Excluded (n = 47) 
• Not mee ng inclusion criteria  
(n = 35) 
• Decl ined to parcipate (n = 12) E
nr
ol
lm
en
t 
A
llo
ca

on
 
Fo
llo
w
-U
p 
Fig. 1 – Flow chart showing enrollment and disposition of the subjects throughout the study
Ryc. 1 – Plan badania
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– as median (minimum, maximum). Two-way ANOVA or
Kruskal–Wallis ANOVA by ranks and median test were used
to compare continuous variables between the three groups.
Chi-square or Fisher's exact test were used for comparison
of categorical (nominal) variables. All differences between
the groups were considered signiﬁcant if p < 0.05. The
statistical analysis was conducted with the use of software
Statistica 8 (StatSoft Inc., 2008; USA).
Results
The groups were not different in terms of average birth
weight, length, head circumference, BMI, Apgar scores, age
and growth parameters at enrolment. Feeding with breast
milk or speciﬁc formula did not produce any reliable effect
on growth within the period of observation.
Initial saliva sIgA levels in infants from the all groups
were similar but after 2 months a signiﬁcant difference
between two formula feeding groups developed. Saliva
concentration of sIgA in infants fed with the formulasupplemented with scGOS/lcFOS was rising like in the
reference (breastfeeding) group. At the same time no
obvious changes were found in infants fed with the formula
without scGOS/lcFOS (Fig. 2).
Concentration of lysozyme in feces of infants from the
breastfeeding group was high at the inclusion into the study
and moderately decreased after 2 months. In infants from
the second and third groups, concentrations of fecal lyso-
zyme were signiﬁcantly lower at the inclusion into the study
comparing to the ﬁrst group. However, after 2 months fecal
lysozyme content was signiﬁcantly higher in infants fed
with the formula supplemented with scGOS/lcFOS than in
babies fed with the standard formula (Fig. 3).
The lowest level of saliva a-1-3 defensin concentration
we identiﬁed in infants was from the breastfeeding group.
Defensins' concentrations in babies fed with the formula
supplemented with scGOS/lcFOS were similar to the values
in the breastfeeding group and signiﬁcantly different from
the values of infants fed with the standard formula. The
increased level of saliva a-1-3 defensins produced by neu-
trophils in infants from the third group may indirectly
indicate formation of pathological bacterial gut colonization
Fig. 4 – Saliva concentrations of a-1-3 defensins (pg/ml) in
infants depending on the type of feeding at the inclusion
into the study and after 2 months (*p < 0.01)
Ryc. 4 – Stężenie a-1-3 defensyny (pg/ml) w ślinie niemowląt w
zależności od rodzaju żywienia- na początku badań i po okresie
2 miesięcy (*p < 0,01)
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Fig. 2 – The level of sIgA (mcg/ml) in saliva depending on the
type of feeding at the inclusion into the study and after
2 months (*p < 0.05)
Ryc. 2 – Poziom sIgA (mcg/ml) w ślinie zależnie od rodzaju
żywienia po włączeniu do badania i po okresie 2 miesięcy
(*p < 0,05)
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(Fig. 4).
Analyzing quantitative features of gut microbiocenosis
we determined that breastfed infants had the highest
content of biﬁdobacteria and lactobacilli in feces (9.047  1.075
and 7.26  0.65 CFU/g accordingly). In infants fed with formula
supplemented with scGOS/lcFOS fecal concentrations of
biﬁdobacteria and lactobacilli were similar to those in breast-
fed infants (8.92  1.011 and 7.22  0.74 CFU/g accordingly).
In infants fed with the standard formula without oligosaccha-
rides concentrations of biﬁdobacteria and lactobacilli in feces0
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Fig. 3 – Concentration of lysozyme in feces (mcg/ml) in
infants depending on the type of feeding at the inclusion
into the study and after 2 months (*p < 0.05)
Ryc. 3 – Stężenie lyzozymu w kale(mcg/ml) u niemowląt
zależnie od rodzaju żywienia po włączeniu do badania i po
okresie 2 miesięcy (*p < 0,05)were signiﬁcantly lower (7.81  0.83 and 6.81  0.93 CFU/g
accordingly; p < 0.05 for the both comparisons) (Table I).
We have also found a higher concentration of Candida
fungi in feces of infants from the third group in comparison
with the other babies (3.97 [0; 7.2] CFU/g vs. 3.65 [0; 5.73]
CFU/g and 3.82 [0; 6.4] CFU/g accordingly in the ﬁrst and
second groups; p > 0.05).
Our results suggest that in infants fed with the formula
supplemented with a speciﬁc mixture of oligosaccharides
(scGOS/lcFOS – 9:1; 8 g/L), the features of intestinal microbio-
cenosis development are similar to those seen in breastfed
babies. It is very important at this age because appropriate
intestinal microbiocenosis formation can inﬂuence child-
ren's health in the future.
Parents of 195 infants agreed to participate in the second
(follow-up) stage of the study. 166 children (51 in the
breastfeeding group, 62 in the scGOS/lcFOS group and 53 in
the formula without oligosaccharides group) completed the
18 months follow-up period (Fig. 1).
Babies were breastfed or received predeﬁned formula for
9.73  3.54; 8.19  3.45 and 8.22  2.99 months accordingly
by groups ( p > 0.05). We did not ﬁnd signiﬁcant differences
between the groups in terms of age at introduction of cow's
milk and the ﬁrst solid foods (Table II).
At the age of 18 months, we analyzed the incidence
of gastrointestinal and upper respiratory tract infections
(URTI). Infants fed with breast milk and with the formula
supplemented with scGOS/lcFOS had similar morbidity
(0.27  0.07 vs. 0.28  0.05 episodes/child/18 months of gas-
trointestinal infections and 2.82  0.96 vs. 2.81  0.51 episo-
des/child/18 months of URTI accordingly; p > 0.05). At the
same time the incidence of gastrointestinal and URT infec-
tions in the second group was signiﬁcantly lower than
in infants fed with the formula without scGOS/lcFOS
(0.28  0.05 vs. 0.78  0.12 episodes/child/18 months and
2.81  0.51 vs. 5.78  0.97 episodes/child/18 months accor-
dingly; p < 0.001) (Fig. 5).
Table II – Infants' age at introduction of unmodified cow's milk and solid foods by the groups
Tabela II – Wiek niemowlęcia w chwili wprowadzenia niemodyfikowanego krowiego mleka i stałego pokarmu w grupach
Group 1
(breast feeding)
Group 2
(formula with scGOS/lcFOS)
Group 3
(standard formula)
p
n 51 62 53
The term of unmodiﬁed
cow's milk introduction (months)*
9.30 (3.68) 8.40 (3.58) 8.17 (3.31) >0.05
The term of solid foods introduction (months)* 5.2 (1.4) 4.68 (0.89) 4.65 (1.19) >0.05
*mean, SD in brackets
*średnia, SD (odchylenie standardowe) w nawiasie
Table III – Comparative frequency of allergic reactions during t
Tabela III – Porównanie częstości występowania reakcji alergicznyc
rodzaju karmienia
Group 1 
n = 51 
Allergic reactions to food* 3.92 (2) 
Allergic reactions to caw's milk protein* 1.96 (1) 
AD* 3.92 (2) 
Respiratory system allergic symptoms* 1.96 (1) 
Gastro-intestinal symptoms of food allergy* 1.96 (1) 
*percentage, number of children in brackets
*procenty, liczba dzieci w nawiasie
Table I – Comparison of fecal Bifidobacteria and Lactobacilli content in infants depending on the type of feeding after 2 months
of study
Tabela I – Porównanie ilości bifidobakterii i Lactobacilli w kale niemowląt w zależności od rodzaju karmienia po 2 miesiącach
Group 1
(breast feeding)
Group 2
(formula with scGOS/lcFOS)
Group 3
(standard formula)
p
Biﬁdobacteria, CFU/g* 9.047 (1.075) 8.92 (1.011) 7.81 (0.83) <0.05
Lactobacilli, CFU/g* 7.26 (0.65) 7.22 (0.74) 6.81 (0.93) <0.05
*mean, SD in brackets
*średnia, SD (odchylenie standardowe) w nawiasie
Fig. 5 – Cumulative incidence of gastrointestinal and upper
respiratory tract infections (URTI) at the age of 18 months
Ryc. 5 – Czestość występowania ostrych infekcji jelitowych
i infekcji górnych dróg oddechowych u dzieci w wieku
18 miesięcy
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supplemented formula had signiﬁcantly less allergic reac-
tions to food products compared to the babies from the
third group (3.92% and 4.84% vs. 16.98% accordingly;
p < 0.05).
Allergic reactions to cow's milk protein were observed
signiﬁcantly rarer in children who were breastfed or recei-
ved supplemented formula in comparison with the third
group (1.96% and 3.23% vs. 15.09% accordingly; p < 0.01). The
incidence of atopic dermatitis (AD), most commonly seen in
allergic infants, was also the highest in babies fed with the
standard formula without oligosaccharides (16.98% vs. 3.92%
and 4.84% accordingly in the ﬁrst and the second groups;
p < 0.05).
There was a similar situation with the respiratory system
allergic symptoms such as recurrent wheezing and with
gastro-intestinal symptoms of food allergy (Table III).
In summary our data suggest that feeding with infant
formula supplemented of with the prebiotic oligosaccharide
mixture (scGOS/lcFOS) during the ﬁrst 6 months can protecthe first 18 months of life depending on the type of feeding
h u dzieci w ciągu pierwszych 18 miesięcy życie w zależności od
Group 2 Group 3 p
n = 62 n = 53
4.84 (3) 16.98 (9) <0.05
3.23 (2) 15.09 (8) <0.05
4.84 (3) 16.98 (9) <0.05
4.84 (3) 13.21 (7) <0.05
3.23 (2) 13.21 (7) <0.05
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during the ﬁrst 18 months of life producing the effect
similar to the effect of breast milk.
Discussion
This study showed that GOS/FOS supplementation inﬂuen-
ced intestinal microbiota and could positively modulate
infant's immune system development and reduce some
allergic and infectious morbidity in infants and toddlers
aged up to 18 months.
In a double-blind randomized placebo-controlled study,
infants received a hypoallergenic whey formula with either
8 g/l GOS/FOS in a 9:1 ratio or 8 g/l maltodextrine (placebo)
for 6 months. At 3 months of age, children were vaccinated
with Hexavac against a.o. diphtheria, tetanus, polio (DTP).
At 6 months of age, plasma samples were collected from 84
infants (verum group n = 41, placebo group n = 43). Levels of
total immunoglobulins (Ig) and of cow's milk protein (CMP-)
and DTP-speciﬁc Ig were measured. GOS/FOS supplementa-
tion led to a signiﬁcant reduction in the plasma level of total
IgE, IgG1, IgG2 and IgG3, whereas no effect on IgG4 was
observed. Concentration of CMP-speciﬁc IgG1 was signiﬁ-
cantly decreased. DTP-speciﬁc immunoglobulin levels were
not affected. This study showed that GOS/FOS supplementa-
tion induced a beneﬁcial antibody proﬁle. GOS/FOS reduced
the total immunoglobulin response and modulated the
immune response toward CMP, while leaving the response to
vaccination intact. This suggests that oral GOS/FOS supple-
mentation is a safe method to restrain the atopic march [12].
The reduced total immunoglobulin levels of the various
isotypes, especially IgE, may be associated with the reduced
incidence of AD in the GOS/FOS supplemented group [10].
This contrasts the study of Kalliomäki et al. [13] who
showed that reduction of the frequency of AD by Lactobacil-
lus rhamnosus GG supplementation was not accompanied by
changes in total or speciﬁc IgE levels. This may suggest that
the prebiotic mixture of GOS/FOS has a stronger immuno-
modulatory potential than this speciﬁc probiotic strain.
Moro reported a signiﬁcant reduction in infant eczema (RR
0.42, 95% CI 0.21, 0.84) up to six months age in infants
receiving a mixture of fructo- and galacto-oligosaccharides
[10].
In a prospective, randomized, double-blind, placebo-con-
trolled design, healthy term infants with a parental history of
atopy were fed either a prebiotic-supplemented (8 g/L scGOS/
lcFOS) or placebo-supplemented (8 g/L maltodextrin) hypoal-
lergenic formula with extensively hydrolyzed cow milk whey
protein during the ﬁrst 6 months of life. Following this
intervention period, blind follow-up continued until two years
of life. During this period, infants in the scGOS/lcFOS group
had signiﬁcantly lower incidence of allergic manifestations.
Cumulative incidences for AD, recurrent wheezing, and
allergic urticaria were higher in the placebo group, (27.9, 20.6,
and 10.3%, respectively) than in the intervention group (13.6,
7.6, and 1.5%) ( p < 0.05). Infants in the scGOS/lcFOS group had
fewer episodes of physician-diagnosed overall and upper
respiratory tract infections ( p < 0.01), fever episodes
( p < 0.00001), and fewer antibiotic prescriptions ( p < 0.05).Early dietary intervention with oligosaccharide prebiotics had
a protective effect against both allergic manifestations and
infections. The observed dual protection lasting beyond the
intervention period suggests that an immune modulating
effect through the intestinal ﬂora modiﬁcation may be the
principal mechanism of action [11].
Conclusions
The mixture of prebiotic oligosaccharides (scGOS/lcFOS – 9:1;
8 g/L) has a similar to breast milk positive impact on the
factors of local protection of mucous membranes such as
lysozyme, a-defensins 1-3, sIgA, intestinal microbiota in
formula-fed infants. This effect may reduce the risk of
allergic and infectious diseases in children aged up to 18
months of life, compared with babies fed with the standard
formula without oligosaccharides.
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